This report studies the global Medical Asparaginase market status and forecast, categorizes the global Medical Asparaginase market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).
Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.
Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.
The classification of Medical Asparaginase includes Escherichia coli, Erwinia Chrysanthemi and Pegylated, and the sales proportion of Escherichia coli in 2017 is about 64.6%, and the proportion is decreasing trend from 2013 to 2018.
Medical Asparaginase is widely sales for Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Others. The most proportion of Medical Asparaginase is sales in Acute Lymphoblastic Leukemia, and the consumption proportion is about 90% in 2017.
Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/265838/global-medical-asparaginase-sales-market
North America is the largest consumption place, with a revenue market share nearly 53.5% in 2017. Following North America, Europe is the second largest consumption place with the revenue market share of 37.2%, China is also an important sales region for the Medical Asparaginase, In China, the price is lower than the developed countries.
Market competition is intense. Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The global Medical Asparaginase market is valued at 390 million US$ in 2017 and will reach 440 million US$ by the end of 2025, growing at a CAGR of 1.4% during 2018-2025.
The major players covered in this report
Jazz Pharmaceuticals
Shire
Medac GmbH
Kyowa Hakko Kirin
Qianhong Bio-pharma
Taj Pharmaceuticals
Mingxing Pharma
SL Pharma
United Biotech
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
United States
Europe
China
Japan
Southeast Asia
India
Request Sample Copy of Report@ https://www.qyresearch.com/sample-form/form/265838/global-medical-asparaginase-sales-market
About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
Media Contact
Company Name: QY Research, Inc.
Contact Person: Rahul Singh
Email: Send Email
Phone: +1 626 295 2442
Address:17890 Castleton Street, Suite 218
City: City of Industry
State: CA 91748
Country: United States
Website: https://www.qyresearch.com/index/detail/265838/global-medical-asparaginase-sales-market